Loading search results
PPP
Sponsor study identifier
observational
520
1 country
1
Study Start
October 1, 2017
Actual (reported)Primary Completion
February 15, 2023
Actual (reported)Study Completion
March 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Background Our understanding of PD has stagnated, partly due to the limited patient diversity and brief followup captured in most study cohorts. Additionally, potentially valuable biomarkers derived from different types of measurements are rarely analyzed in an integrated fashion. Objective This study aims to create a longitudinal dataset of clinical, molecular, imaging, and continuous wearable sensor-based data from a representative Parkinson's disease (PD) cohort. Data will be made available to researchers worldwide to accelerate the discovery of novel etiological insights, development of new therapeutic approaches, and personalized disease management. For this purpose, an extensible norm for sharing research data will be developed, meeting the latest data privacy and security standards. Methods Supported by a multinational, public-private partnership, a prospective cohort study was designed to include 650 representative PD patients (disease duration \<5 years). Comprehensive follow-up for at least 2 years includes: (1) annual assessment at the study center for acquisition of detailed clinimetric data, magnetic resonance imaging, and biospecimens (plasma, serum, cerebrospinal fluid (CSF), stool) and (2) collection of data from the home environment, using self-assessments and an advanced wrist-worn wearable device to continuously measure biological and environmental signals. Collection, storage, and sharing of these research data will be facilitated by a new method to protect privacy and enhance security using polymorphic encryption and pseudonymization (PEP), a methodology that combines advanced encryption with distributed pseudonymization and data access management. Conclusion This study is unique, as it includes a cohort of unbiased subjects with recently diagnosed PD, creating an unprecedented dataset that combines longitudinally collected clinical, molecular, imaging, and data from wearable sensors using state of the art technology. The single-center study design minimizes measurement variability. Finally, the innovative methodology for data privacy and protection might serve as a new international standard for sharing research data.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 1, 2017
Actual (reported)November 23, 2017
Actual (reported)December 7, 2017
Actual (reported)February 15, 2023
Actual (reported)March 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Short-term disease progression in terms of motor symptoms
Change in Movement Disorders Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III score, measured in off state. This scale assesses 18 motor symptoms (33 items) that are specific for Parkinson's disease. Item scores range from 0 to 4 and are summed, resulting in a total score ranging from 0 to 132, with higher scores representing worse outcomes.
From baseline till 1 year follow-up
Short-term disease progression in terms of cognitive functioning
Change in Montreal Cognitive Assessment (MoCA) score. The MoCa assesses in 30 items different types of cognitive abilities (0-1 scale), including orientation, short-term memory and attention. All items are summed, resulting in a total score ranging from 0 to 30, with higher scores representing better outcomes.
From baseline till 1 year follow-up
Mid-term disease progression in terms of motor symptoms
Change in MDS-UPDRS part III score, measured in off state.
From baseline till 2 year follow-up
Mid-term disease progression in terms of cognitive functioning
Change in Montreal Cognitive Assessment (MoCA) score
From baseline till 2 year follow-up
Any person with Parkinson's disease who meets the inclusion criteria and does not meet the exclusion criteria.
Radboud university medical center
Nijmegen, 6500 HB, Netherlands
Heye K, Li R, Bai Q, St George RJ, Rudd K, Huang G, Meinders MJ, Bloem BR, Alty JE. Validation of computer vision technology for analyzing bradykinesia in outpatient clinic videos of people with Parkinson's disease. J Neurol Sci. 2024 Nov 15;466:123271. doi: 10.1016/j.jns.2024.123271. Epub 2024 Oct 15.
Bloem BR, Marks WJ Jr, Silva de Lima AL, Kuijf ML, van Laar T, Jacobs BPF, Verbeek MM, Helmich RC, van de Warrenburg BP, Evers LJW, intHout J, van de Zande T, Snyder TM, Kapur R, Meinders MJ. The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson's disease. BMC Neurol. 2019 Jul 17;19(1):160. doi: 10.1186/s12883-019-1394-3.
Blood specimen and stool collection from all enrolled patients and cerebrospinal fluid (CSF) from patients who have provided additional and optional consent to CSF collection, for longitudinal genotypic and phenotypic assays.
Bastiaan R Bloem, MD, PhD
Radboud university medical center, department of neurology
520 participants (actual enrollment reported by the registry).
First Submitted
November 23, 2017
First Posted
December 7, 2017
Study Start
October 1, 2017
Actual (reported)Contact the study team to confirm eligibility.
Primary Completion
February 15, 2023
Actual (reported)Study Completion
March 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
March 24, 2025
Record last verified: 2025-03
The dataset generated in this study will become available to qualified researchers worldwide, provided research questions are approved by the Research and Data Sharing Review Committee (RDSRC). The RDSRC will protect subjects' privacy by limiting the availability of the study data and controlling access to sources of information that might potentially be used to identify the individual subjects associated with the biospecimen analysis. The RDSRC will assess the relevance and scientific quality of research proposals for which study data or material is requested. These responsibilities include the consideration of applications for: * access to the resources obtained in this study, including data or biomaterials * applications for endorsement of a scientific project using study materials; * applications for endorsement of a clinical study using study materials.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: